Ther Innov Regul Sci
Improving Clinical Trial Participant Prescreening With Artificial Intelligence (AI): A Comparison of the Results of AI-Assisted vs Standard Methods in 3 Oncology Trials.
Calaprice-Whitty D, Galil K, Salloum W, Zariv A, Jimenez B
Delays in clinical trial enrollment and difficulties enrolling representative samples continue to vex sponsors, sites, and patient populations. Here w ...
Read More
Source: PubMed
Eur J Radiol
CT Halo sign: A systematic review.
Ray A, Mittal A, Vyas S
The CT Halo sign or Halo sign (HS) refers to ground-glass opacity surrounding a nodule or mass in the lung parenchyma. We conducted a systematic revie ...
Read More
Source: PubMed
Eur. J. Cancer
Inflammatory myofibroblastic tumor: The experience of the European pediatric Soft Tissue Sarcoma Study Group (EpSSG).
Casanova M, Brennan B, Alaggio R, Kelsey A, Orbach D, van Noesel MM, Corradini N, Minard-Colin V, Zanetti I, Bisogno G, Gallego S, Merks JHM, De Salvo GL, Ferrari A
We report the clinical findings and results of treatment in the cohort of patients with inflammatory myofibroblastic tumor (IMT) managed according to ...
Read More
Source: PubMed
Lung Cancer
Cytology for PD-L1 testing: A systematic review.
Gosney JR, Boothman AM, Ratcliffe M, Kerr KM
Evaluation of tumoral programmed cell death ligand-1 (PD-L1) expression is standard practice for patients with advanced non-small-cell lung cancer (NS ...
Read More
Source: PubMed
J Med Imaging Radiat Sci 2020 Jan 29
Exploring Tobacco Use and Smoking Cessation Best Practices From the Perspectives of Individuals With Lung Cancer and Health Care Professionals.
Weiss Y, Bristow B, Karol DL, Fitch M, McAndrew A, Gibson L, Court A, Curle E, Di Prospero L
Lung cancer patients who continue to smoke after diagnosis are at increased risk of treatment toxicity, residual/recurrent disease, future malignancie ...
Read More
Source: PubMed
Ther Innov Regul Sci
Improving Clinical Trial Participant Prescreening With Artificial Intelligence (AI): A Comparison of the Results of AI-Assisted vs Standard Methods in 3 Oncology Trials.
Calaprice-Whitty D, Galil K, Salloum W, Zariv A, Jimenez B
Delays in clinical trial enrollment and difficulties enrolling representative samples continue to vex sponsors, sites, and patient populations. Here w ...
Read More
Source: PubMed
Eur J Radiol
CT Halo sign: A systematic review.
Ray A, Mittal A, Vyas S
The CT Halo sign or Halo sign (HS) refers to ground-glass opacity surrounding a nodule or mass in the lung parenchyma. We conducted a systematic revie ...
Read More
Source: PubMed
Eur. J. Cancer
Inflammatory myofibroblastic tumor: The experience of the European pediatric Soft Tissue Sarcoma Study Group (EpSSG).
Casanova M, Brennan B, Alaggio R, Kelsey A, Orbach D, van Noesel MM, Corradini N, Minard-Colin V, Zanetti I, Bisogno G, Gallego S, Merks JHM, De Salvo GL, Ferrari A
We report the clinical findings and results of treatment in the cohort of patients with inflammatory myofibroblastic tumor (IMT) managed according to ...
Read More
Source: PubMed
Lung Cancer
Cytology for PD-L1 testing: A systematic review.
Gosney JR, Boothman AM, Ratcliffe M, Kerr KM
Evaluation of tumoral programmed cell death ligand-1 (PD-L1) expression is standard practice for patients with advanced non-small-cell lung cancer (NS ...
Read More
Source: PubMed
J Med Imaging Radiat Sci 2020 Jan 29
Exploring Tobacco Use and Smoking Cessation Best Practices From the Perspectives of Individuals With Lung Cancer and Health Care Professionals.
Weiss Y, Bristow B, Karol DL, Fitch M, McAndrew A, Gibson L, Court A, Curle E, Di Prospero L
Lung cancer patients who continue to smoke after diagnosis are at increased risk of treatment toxicity, residual/recurrent disease, future malignancie ...
Read More
Source: PubMed
